Reference14 articles.
1. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012
2. Improved survival with MEK inhibition in BRAF-mutated melanoma;Flaherty;N Engl J Med,2012
3. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma;Chapman;J Clin Oncol,2012
4. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma;Menzies;Clin Cancer Res,2012
5. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region;Amanuel;Pathology,2012
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献